Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo [d] [1, 3] dioxol-4-yl) piperidin-1-yl) methyl)-1-(((s)-oxetan-2-yl) methyl)-1h-benzo [d] imidazol-6-carboxylic acid, 1, 3-dihydroxy-2-(hydroxymethyl) propan-2-amine salt
The present invention provides solid forms of 2-((4-((S)-2-(5-chloropyridin-2-yl)-2-methylbenzo [d] [1, 3] dioxol-4-yl) piperidin-1-yl) methyl)-1-(((S)-oxetan-2-yl) methyl)-1H-benzo [d] imidazol-6-carboxylic acid, a 1, 3-dihydroxy-2-(hydroxymethyl) propan-2-amine salt, for example, a salt of a compo...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | chi ; eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | BARLEY SCOTT W GRIFFITH DAVID ANDREW CURTO JOHN M LIAN YAJING MATHIOWETZ ALAN M PIOTROWSKI DAVID W RUGGERI ROGER BENJAMIN ASPNES GARY ERIK FUTAKI, KENTARO EDMONDS DAVID J CLARK WILLIAM D LIMBERAKIS CHRIS FLANAGAN MARK EDWARD RONREGAN AARON T WARD KEVIN |
| description | The present invention provides solid forms of 2-((4-((S)-2-(5-chloropyridin-2-yl)-2-methylbenzo [d] [1, 3] dioxol-4-yl) piperidin-1-yl) methyl)-1-(((S)-oxetan-2-yl) methyl)-1H-benzo [d] imidazol-6-carboxylic acid, a 1, 3-dihydroxy-2-(hydroxymethyl) propan-2-amine salt, for example, a salt of a compound represented by formula (I). A crystalline form (e.g., Form 2 or Form 3) or an amorphous form of a hydrate (e.g., a monohydrate); and pharmaceutical compositions and their use in the treatment of diseases, conditions or disorders modulated by GLP-1R in mammals, such as humans.
本发明提供了2-((4-((S)-2-(5-氯吡啶-2-基)-2-甲基苯并[d][1,3]二氧杂环戊烯-4-基)哌啶-1-基)甲基)-1-(((S)-氧杂环丁烷-2-基)甲基)-1H-苯并[d]咪唑-6-甲酸,1,3-二羟基-2-(羟基甲基)丙烷-2-胺盐的固体形式，例如，水合物(例如一水合物)结晶形式(例如形式2或形式3)或无定形形式；以及药物组合物，及其在哺乳动物诸如人中治疗由GLP-1R调节的疾病、病症或障碍的用途。 |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CN115175893A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CN115175893A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CN115175893A3</originalsourceid><addsrcrecordid>eNqNjr9qwzAQxr10KGnf4bI5YA2q4zYZg2np1KXdQgiKdMYHsk9IHqy8cl-ismPI2uG4v9_vvsfs95stGWjYdwG4gReR59sUYSNSWQndWvbsoidDfRpFOy06HNpoL9hfGY7mBEdZQHkCQzyyFdvpChw5vKnk3N80m9TlM55HHNSCvC9bcadSR0ZdE_BVaOUvPEZLGpQmU8D0UBhqo_FpPnldyoUELrme8aqjHiEoOzxlD42yAZ-XvMrWH-8_9adAx2cMTmnscTjXX1JW8q3a7ctD-Z-bPyqvZ8Y</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo [d] [1, 3] dioxol-4-yl) piperidin-1-yl) methyl)-1-(((s)-oxetan-2-yl) methyl)-1h-benzo [d] imidazol-6-carboxylic acid, 1, 3-dihydroxy-2-(hydroxymethyl) propan-2-amine salt</title><source>esp@cenet</source><creator>BARLEY SCOTT W ; GRIFFITH DAVID ANDREW ; CURTO JOHN M ; LIAN YAJING ; MATHIOWETZ ALAN M ; PIOTROWSKI DAVID W ; RUGGERI ROGER BENJAMIN ; ASPNES GARY ERIK ; FUTAKI, KENTARO ; EDMONDS DAVID J ; CLARK WILLIAM D ; LIMBERAKIS CHRIS ; FLANAGAN MARK EDWARD ; RONREGAN AARON T ; WARD KEVIN</creator><creatorcontrib>BARLEY SCOTT W ; GRIFFITH DAVID ANDREW ; CURTO JOHN M ; LIAN YAJING ; MATHIOWETZ ALAN M ; PIOTROWSKI DAVID W ; RUGGERI ROGER BENJAMIN ; ASPNES GARY ERIK ; FUTAKI, KENTARO ; EDMONDS DAVID J ; CLARK WILLIAM D ; LIMBERAKIS CHRIS ; FLANAGAN MARK EDWARD ; RONREGAN AARON T ; WARD KEVIN</creatorcontrib><description>The present invention provides solid forms of 2-((4-((S)-2-(5-chloropyridin-2-yl)-2-methylbenzo [d] [1, 3] dioxol-4-yl) piperidin-1-yl) methyl)-1-(((S)-oxetan-2-yl) methyl)-1H-benzo [d] imidazol-6-carboxylic acid, a 1, 3-dihydroxy-2-(hydroxymethyl) propan-2-amine salt, for example, a salt of a compound represented by formula (I). A crystalline form (e.g., Form 2 or Form 3) or an amorphous form of a hydrate (e.g., a monohydrate); and pharmaceutical compositions and their use in the treatment of diseases, conditions or disorders modulated by GLP-1R in mammals, such as humans.
本发明提供了2-((4-((S)-2-(5-氯吡啶-2-基)-2-甲基苯并[d][1,3]二氧杂环戊烯-4-基)哌啶-1-基)甲基)-1-(((S)-氧杂环丁烷-2-基)甲基)-1H-苯并[d]咪唑-6-甲酸,1,3-二羟基-2-(羟基甲基)丙烷-2-胺盐的固体形式，例如，水合物(例如一水合物)结晶形式(例如形式2或形式3)或无定形形式；以及药物组合物，及其在哺乳动物诸如人中治疗由GLP-1R调节的疾病、病症或障碍的用途。</description><language>chi ; eng</language><subject>ACYCLIC OR CARBOCYCLIC COMPOUNDS ; CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20221011&DB=EPODOC&CC=CN&NR=115175893A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25562,76317</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20221011&DB=EPODOC&CC=CN&NR=115175893A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>BARLEY SCOTT W</creatorcontrib><creatorcontrib>GRIFFITH DAVID ANDREW</creatorcontrib><creatorcontrib>CURTO JOHN M</creatorcontrib><creatorcontrib>LIAN YAJING</creatorcontrib><creatorcontrib>MATHIOWETZ ALAN M</creatorcontrib><creatorcontrib>PIOTROWSKI DAVID W</creatorcontrib><creatorcontrib>RUGGERI ROGER BENJAMIN</creatorcontrib><creatorcontrib>ASPNES GARY ERIK</creatorcontrib><creatorcontrib>FUTAKI, KENTARO</creatorcontrib><creatorcontrib>EDMONDS DAVID J</creatorcontrib><creatorcontrib>CLARK WILLIAM D</creatorcontrib><creatorcontrib>LIMBERAKIS CHRIS</creatorcontrib><creatorcontrib>FLANAGAN MARK EDWARD</creatorcontrib><creatorcontrib>RONREGAN AARON T</creatorcontrib><creatorcontrib>WARD KEVIN</creatorcontrib><title>Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo [d] [1, 3] dioxol-4-yl) piperidin-1-yl) methyl)-1-(((s)-oxetan-2-yl) methyl)-1h-benzo [d] imidazol-6-carboxylic acid, 1, 3-dihydroxy-2-(hydroxymethyl) propan-2-amine salt</title><description>The present invention provides solid forms of 2-((4-((S)-2-(5-chloropyridin-2-yl)-2-methylbenzo [d] [1, 3] dioxol-4-yl) piperidin-1-yl) methyl)-1-(((S)-oxetan-2-yl) methyl)-1H-benzo [d] imidazol-6-carboxylic acid, a 1, 3-dihydroxy-2-(hydroxymethyl) propan-2-amine salt, for example, a salt of a compound represented by formula (I). A crystalline form (e.g., Form 2 or Form 3) or an amorphous form of a hydrate (e.g., a monohydrate); and pharmaceutical compositions and their use in the treatment of diseases, conditions or disorders modulated by GLP-1R in mammals, such as humans.
本发明提供了2-((4-((S)-2-(5-氯吡啶-2-基)-2-甲基苯并[d][1,3]二氧杂环戊烯-4-基)哌啶-1-基)甲基)-1-(((S)-氧杂环丁烷-2-基)甲基)-1H-苯并[d]咪唑-6-甲酸,1,3-二羟基-2-(羟基甲基)丙烷-2-胺盐的固体形式，例如，水合物(例如一水合物)结晶形式(例如形式2或形式3)或无定形形式；以及药物组合物，及其在哺乳动物诸如人中治疗由GLP-1R调节的疾病、病症或障碍的用途。</description><subject>ACYCLIC OR CARBOCYCLIC COMPOUNDS</subject><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjr9qwzAQxr10KGnf4bI5YA2q4zYZg2np1KXdQgiKdMYHsk9IHqy8cl-ismPI2uG4v9_vvsfs95stGWjYdwG4gReR59sUYSNSWQndWvbsoidDfRpFOy06HNpoL9hfGY7mBEdZQHkCQzyyFdvpChw5vKnk3N80m9TlM55HHNSCvC9bcadSR0ZdE_BVaOUvPEZLGpQmU8D0UBhqo_FpPnldyoUELrme8aqjHiEoOzxlD42yAZ-XvMrWH-8_9adAx2cMTmnscTjXX1JW8q3a7ctD-Z-bPyqvZ8Y</recordid><startdate>20221011</startdate><enddate>20221011</enddate><creator>BARLEY SCOTT W</creator><creator>GRIFFITH DAVID ANDREW</creator><creator>CURTO JOHN M</creator><creator>LIAN YAJING</creator><creator>MATHIOWETZ ALAN M</creator><creator>PIOTROWSKI DAVID W</creator><creator>RUGGERI ROGER BENJAMIN</creator><creator>ASPNES GARY ERIK</creator><creator>FUTAKI, KENTARO</creator><creator>EDMONDS DAVID J</creator><creator>CLARK WILLIAM D</creator><creator>LIMBERAKIS CHRIS</creator><creator>FLANAGAN MARK EDWARD</creator><creator>RONREGAN AARON T</creator><creator>WARD KEVIN</creator><scope>EVB</scope></search><sort><creationdate>20221011</creationdate><title>Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo [d] [1, 3] dioxol-4-yl) piperidin-1-yl) methyl)-1-(((s)-oxetan-2-yl) methyl)-1h-benzo [d] imidazol-6-carboxylic acid, 1, 3-dihydroxy-2-(hydroxymethyl) propan-2-amine salt</title><author>BARLEY SCOTT W ; GRIFFITH DAVID ANDREW ; CURTO JOHN M ; LIAN YAJING ; MATHIOWETZ ALAN M ; PIOTROWSKI DAVID W ; RUGGERI ROGER BENJAMIN ; ASPNES GARY ERIK ; FUTAKI, KENTARO ; EDMONDS DAVID J ; CLARK WILLIAM D ; LIMBERAKIS CHRIS ; FLANAGAN MARK EDWARD ; RONREGAN AARON T ; WARD KEVIN</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CN115175893A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2022</creationdate><topic>ACYCLIC OR CARBOCYCLIC COMPOUNDS</topic><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>BARLEY SCOTT W</creatorcontrib><creatorcontrib>GRIFFITH DAVID ANDREW</creatorcontrib><creatorcontrib>CURTO JOHN M</creatorcontrib><creatorcontrib>LIAN YAJING</creatorcontrib><creatorcontrib>MATHIOWETZ ALAN M</creatorcontrib><creatorcontrib>PIOTROWSKI DAVID W</creatorcontrib><creatorcontrib>RUGGERI ROGER BENJAMIN</creatorcontrib><creatorcontrib>ASPNES GARY ERIK</creatorcontrib><creatorcontrib>FUTAKI, KENTARO</creatorcontrib><creatorcontrib>EDMONDS DAVID J</creatorcontrib><creatorcontrib>CLARK WILLIAM D</creatorcontrib><creatorcontrib>LIMBERAKIS CHRIS</creatorcontrib><creatorcontrib>FLANAGAN MARK EDWARD</creatorcontrib><creatorcontrib>RONREGAN AARON T</creatorcontrib><creatorcontrib>WARD KEVIN</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>BARLEY SCOTT W</au><au>GRIFFITH DAVID ANDREW</au><au>CURTO JOHN M</au><au>LIAN YAJING</au><au>MATHIOWETZ ALAN M</au><au>PIOTROWSKI DAVID W</au><au>RUGGERI ROGER BENJAMIN</au><au>ASPNES GARY ERIK</au><au>FUTAKI, KENTARO</au><au>EDMONDS DAVID J</au><au>CLARK WILLIAM D</au><au>LIMBERAKIS CHRIS</au><au>FLANAGAN MARK EDWARD</au><au>RONREGAN AARON T</au><au>WARD KEVIN</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo [d] [1, 3] dioxol-4-yl) piperidin-1-yl) methyl)-1-(((s)-oxetan-2-yl) methyl)-1h-benzo [d] imidazol-6-carboxylic acid, 1, 3-dihydroxy-2-(hydroxymethyl) propan-2-amine salt</title><date>2022-10-11</date><risdate>2022</risdate><abstract>The present invention provides solid forms of 2-((4-((S)-2-(5-chloropyridin-2-yl)-2-methylbenzo [d] [1, 3] dioxol-4-yl) piperidin-1-yl) methyl)-1-(((S)-oxetan-2-yl) methyl)-1H-benzo [d] imidazol-6-carboxylic acid, a 1, 3-dihydroxy-2-(hydroxymethyl) propan-2-amine salt, for example, a salt of a compound represented by formula (I). A crystalline form (e.g., Form 2 or Form 3) or an amorphous form of a hydrate (e.g., a monohydrate); and pharmaceutical compositions and their use in the treatment of diseases, conditions or disorders modulated by GLP-1R in mammals, such as humans.
本发明提供了2-((4-((S)-2-(5-氯吡啶-2-基)-2-甲基苯并[d][1,3]二氧杂环戊烯-4-基)哌啶-1-基)甲基)-1-(((S)-氧杂环丁烷-2-基)甲基)-1H-苯并[d]咪唑-6-甲酸,1,3-二羟基-2-(羟基甲基)丙烷-2-胺盐的固体形式，例如，水合物(例如一水合物)结晶形式(例如形式2或形式3)或无定形形式；以及药物组合物，及其在哺乳动物诸如人中治疗由GLP-1R调节的疾病、病症或障碍的用途。</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | chi ; eng |
| recordid | cdi_epo_espacenet_CN115175893A |
| source | esp@cenet |
| subjects | ACYCLIC OR CARBOCYCLIC COMPOUNDS CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo [d] [1, 3] dioxol-4-yl) piperidin-1-yl) methyl)-1-(((s)-oxetan-2-yl) methyl)-1h-benzo [d] imidazol-6-carboxylic acid, 1, 3-dihydroxy-2-(hydroxymethyl) propan-2-amine salt |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T13%3A31%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=BARLEY%20SCOTT%20W&rft.date=2022-10-11&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECN115175893A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |